OTBB Director Sarah Yim said regulators need a framework for determining when comparative efficacy trials are necessary for biosimilar approval. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
